Article Details
Retrieved on: 2022-04-19 11:46:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Based on pivotal DESTINY-Lung01 results showing AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated a 54.9% tumor response rate.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here